Aptevo Therapeutics Inc. (APVO): Cost of Revenue

Annual figures by period end, from SEC filings.

Partial revenue. In this company's filings, net income for the year ended 2022-12-31 is larger than reported revenue. The revenue it tags covers only part of its income (banks and REITs often tag only fee income this way, leaving out interest or rent), so it is not the company's whole top line. Margins on it are not computed, and it is left out of revenue rankings.

Older than the company's other figures. The latest Cost of Revenue is for the year ended 2019-12-31, while the company's latest annual report covers the year ended 2025-12-31. Its later filings do not report this line under the concept TickerFacts maps.

$19.93M
Year ended 2019-12-31
2018-12-31: $11.21M2019-12-31: $19.93M$19.93M
2018-12-31 Cost of Revenue (USD) 2019-12-31
Period endedCost of RevenueChange YoYSource filing
2019-12-31$19.93M+77.7%2020-03-25, From 2019-01-01
2018-12-31$11.21Mn/a2020-03-25, From 2018-01-01